"It highlights the importance these methods hold." Researchers reveal groundbreaking method to predict how childhood health ...

Scientists have discovered new fat cell subpopulations with specialized functions, revealing differences between subcutaneous ...

Glucagon-like peptite-1 (GLP-1) receptor agonists, such as Wegovy and Ozempic, have taken the food industry by storm. With ...

Discover the surprising ways alcohol impacts your liver, how the vital organ fights back against damage, and what you can do ...

Ctexli’s approval further entrenches Mirum as a leader in rare liver diseases, alongside its cornerstone product Livmarli and ...

A team of University of New Mexico scientists found that the human brain is the organ with the highest concentration of microplastics and nanoplastics compared to the liver or kidney. The study, led ...

The U.S. Food and Drug Administration (FDA) has announced its recent approval of Ctexli (chenodiol), marking the first-ever treatment for cerebrotendinous xanthomatosis (CTX), a rare and debilitating ...

In the grand theater of human health, the liver plays a starring role, yet it rarely gets the spotlight it deserves. This ...

Ultra Liver is a highly active support supplement in the facilitation of liver health, liver function, and detoxification.

Chenodiol -- a naturally occurring human bile acid also known as chenodeoxycholic acid -- is the first FDA-approved drug indicated for the rare lipid storage disease and autosomal recessive genetic ...

The firm plans to build on its organ and tissue modeling technology to develop more sophisticated tests, including full-body digital twins.

Mirum Pharmaceuticals' Ctexli wins FDA approval for CTX, a rare lipid storage disease. The company projects 2025 global sales of $420–$435 million.